Andrés Jerez

NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy

J. Hernández-Rivas, T. Chen-Liang, H. Martínez-Banaclocha, 2023, Cell reports. Medicine.